Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications - reassuring insights from the United Kingdom PREPARE-IBD multi centre cohort study
Authors
Lamb, CASebastian, S
Kent, AJ
Segal, JP
Gonzalez, HA
Brookes, MJ
Mehta, SJ
Subramanian, S
Bhala, N
Hicks, LC
Conley, TE
Patel, KV
Walker, GJ
Kennedy, NA
PREPARE-IBD STUDY GROUOP
Issue Date
2021-05-07
Metadata
Show full item recordCitation
Lamb, C.A., Sebastian, S., Kent, A.J. et al. (2021) Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications - reassuring insights from the United Kingdom PREPARE-IBD multi centre cohort study. Alimentary Pharmacology and Therapeutics, 53(11), pp. 1236-1240. https://doi.org/10.1111/apt.16349Publisher
Wiley-BlackwellJournal
Alimentary Pharmacology and TherapeuticsAdditional Links
https://onlinelibrary.wiley.com/doi/full/10.1111/apt.16349Type
OtherLanguage
enDescription
This is an accepted manuscript of an article published by Wiley in Alimentary Pharmacology and Therapeutics, available online at: https://doi.org/10.1111/apt.16349 The accepted version of the publication may differ from the final published version.ISSN
0269-2813ae974a485f413a2113503eed53cd6c53
10.1111/apt.16349
Scopus Count
Collections
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/